Monoclonal antibody prevents graft-vs-host disease in bone marrow transplantation model

New research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease, a potentially lethal complication of bone marrow stem cell transplantation. CytoDyn is currently enrolling patients in a Phase 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation. …read more

Source: EurekAlert

(Visited 3 times, 1 visits today)

Popular Posts